End Price Gouging for Medications Act

This bill sets annual reference prices for prescription drugs based on prices in other countries (like Germany, Japan, and Canada), requiring drug manufacturers to sell covered medications at or below these reference prices within federal health programs. It directly affects Medicare, Medicaid, CHIP, TRICARE, VA care, federal employee health plans, and Indian Health Service programs. Manufacturers must offer drugs at the reference price to all patients, including those without insurance or in private plans, with violations triggering civil penalties of 5 times the revenue difference. Collected penalties fund NIH drug research, applying to both brand and generic drugs approved by the FDA.